Spero Therapeutics announced its financial results for the third quarter ended September 30, 2024, on November 14, 2024. The company reported an ending cash balance of $76.3 million for Q3 2024.
The company reiterated its cash runway guidance, stating that existing cash and cash equivalents are expected to fund operations into mid-2026. This financial outlook follows a recent restructuring and workforce reduction.
Regarding its pipeline, Spero confirmed that enrollment in the Phase 3 PIVOT-PO trial for tebipenem HBr is progressing and remains on track to complete in the second half of 2025. Development plans for SPR720 are suspended, and the SPR206 program continues, contingent on non-dilutive funding.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.